Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials

by Furie, Richard, Petri, Michelle A, Strand, Vibeke, Gladman, Dafna D, Zhong, Z John, Freimuth, William W
Published 2014

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

by van Vollenhoven, Ronald F, Petri, Michelle A, Cervera, Ricard, Roth, David A, Ji, Beulah N, Kleoudis, Christi S, Zhong, Z John, Freimuth, William
Published 2012

Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus fro...

by Strand, Vibeke, Levy, Roger A, Cervera, Ricard, Petri, Michelle A, Birch, Helen, Freimuth, William W, Zhong, Z John, Clarke, Ann E
Published 2014

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined result...

by Manzi, Susan, Sánchez-Guerrero, Jorge, Merrill, Joan T, Furie, Richard, Gladman, Dafna, Navarra, Sandra V, Ginzler, Ellen M, D'Cruz, David P, Doria, Andrea, Cooper, Simon, Zhong, Z John, Hough, Douglas, Freimuth, William, Petri, Michelle A
Published 2012